Building permit Nuclear Health Centre obtained

17 December 2020

We are proud to announce that the building permit has been obtained for the Nuclear Health Centre (NHC) on the Energy & Health Campus in Petten. On June 8, PALLAS submitted an application to the municipality of Schagen for a building permit for the NHC, a production facility that is important for the production and development of nuclear medicines.

Today, the municipality approved this application and the building permit has been issued. Construction is expected to start in 2021. The permit is now being made available for inspection.
The NHC has currently issued three tenders: a tender for the construction of the building and the installations, a second tender for the clean rooms and the third tender for the hot cells. The NHC is expected to open its doors in 2022.

Every day, 30,000 patients are depending on the production of medical radioisotopes in a small town in Noord-Holland, called Petten. This number is only expected to increase due to new treatments with medical isotopes from reactors and the increased number of patients suffering from cancerous and cardiac diseases all over the world. In addition to the irradiation of products, there is also an urgent need of production facilities processing irradiated raw materials into semi-finished products (radiochemicals) medical device products and/or into medicines (radiopharmaceuticals). Therefore, PALLAS has initiated the construction of both the PALLAS-reactor and the NHC in Petten. Obtaining the building permit is an important milestone in the realisation of the production facility. The NHC’s design was focused on a flexible infrastructure, thus offering its clients customized solutions for processing various isotope groups, like alpha, beta and gamma, into radiochemicals, medical device products and/or radiopharmaceuticals.

The NHC will be realised in the vicinity of the current reactor (the High Flux Reactor) and the future PALLAS-reactor. The NHC will be complementary to the FIELD-LAB (a research facility for nuclear medicine) of NRG and other labs at the Energy & Health Campus. The accessory advantage will be the integrated supply chain and, consequently, the efficient handling of materials, nuclear fallout of irradiated products, radioactive transport and waste, and the benefit of existing nuclear knowhow and experience present within the different nuclear companies at the campus.